Jasper Therapeutics (NASDAQ:JSPR) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Jasper Therapeutics (NASDAQ:JSPR) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities research analysts have also recently issued research reports about the company. William Blair began coverage on Jasper Therapeutics in a research note on Wednesday, October 14th. They set an “outperform” rating for the company. Piper Sandler started coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They issued an “overweight” rating and a $60.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $220.00.

Jasper Therapeutics Stock Up 2.3%

NASDAQ:JSPR traded up $0.31 on Friday, hitting $13.68. The stock had a trading volume of 16,495 shares, compared to its average volume of 24,453. The stock has a market cap of $15.18 million, a price-to-earnings ratio of -0.29 and a beta of 3.30. The company has a fifty day moving average price of $16.79 and a two-hundred day moving average price of $24.15. Jasper Therapeutics has a 1-year low of $9.45 and a 1-year high of $72.60.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Friday, August 14th. The company reported ($3.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.03) by $5.03. As a group, analysts anticipate that Jasper Therapeutics will post -28.98 earnings per share for the current year.

About Jasper Therapeutics

Jasper Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for conditions involving blood-forming stem cells and mast cells. Its research focuses on c-Kit, also known as CD117, a protein found on these cells. The company’s lead investigational drug, briquilimab (formerly JSP191), is a monoclonal antibody that targets c-Kit. Jasper has studied briquilimab as a conditioning treatment for stem cell transplantation and gene therapy, and is evaluating it for mast cell-mediated diseases, including chronic spontaneous urticaria.